Suchergebnisse - (Subject:"Prednisone")

PubPharm (30)

1

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER) : a randomised, phase 3, non-inferiority trial

enthalten in: Lancet (London, England) | 2019

von Poeschel, V. | Held, G. | Ziepert, M. | +43

CommentIn: Lancet. 2020 Dec 21;394(10216):2208-2209. - PMID 31868615

2

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Horwitz, S. | O'Connor, O. | Pro, B. | +129

CommentIn: Lancet. 2019 Jan 19;393(10168):201-202. - PMID 30663580

3

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18) : final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

enthalten in: Lancet (London, England) | 2017

von Borchmann, P. | Goergen, H. | Kobe, C. | +33

CommentIn: Lancet. 2018 Dec 23;390(10114):2744-2745. - PMID 29061298

4

An unusual extranodal T-cell non-Hodgkin lymphoma

enthalten in: Lancet (London, England) | 2016

von Coats, J. | Mackie, A. | Kernohan, N. | +4

CommentIn: Lancet. 2016 Sep 10;388(10049):1128. - PMID 27628521

5

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger) : a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

enthalten in: Lancet (London, England) | 2016

von Hermine, O. | Hoster, E. | Walewski, J. | +35

CommentIn: Lancet. 2016 Aug 6;388(10044):535-6. - PMID 27313085

6

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma : a randomised, controlled, open-label, phase 3 trial

enthalten in: Lancet (London, England) | 2016

von Ribrag, V. | Koscielny, S. | Bosq, J. | +19

CommentIn: Lancet. 2016 Jun 11;387(10036):2360-1. - PMID 27080497

7

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma : a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

enthalten in: Lancet (London, England) | 2013

von Cunningham, D. | Hawkes, E. | Jack, A. | +13

CommentIn: Lancet. 2013 May 25;381(9880):1793-4. - PMID 23615460

8

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicentre, randomised, phase 3 non-inferiority trial

enthalten in: Lancet (London, England) | 2013

von Rummel, M. | Niederle, N. | Maschmeyer, G. | +118

ErratumIn: Lancet. 2013 Apr 6;381(9873):1184

9

Escalated BEACOPP in advanced Hodgkin's lymphoma

enthalten in: Lancet (London, England) | 2012

von Casasnovas, O. | Coiffier, B.

CommentOn: Lancet. 2012 May 12;379(9828):1791-9. - PMID 22480758

10

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial) : a randomised, open-label, phase 3 non-inferiority trial

enthalten in: Lancet (London, England) | 2012

von Engert, A. | Haverkamp, H. | Kobe, C. | +31

ErratumIn: Lancet. 2012 May 12;379(9828):1790